Company: BIAF
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024163
Chunk: 3

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 3
---
 (2,104,860) 
     (6,683,525) 
     (4,063,003)

    Income tax expense 
     28,984  
     5,419  
     37,679  
     9,091 

    Net loss 
    $(4,060,787) 
    $(2,110,279) 
    $(6,721,204) 
    $(4,072,094)

    Net loss per common share, basic and diluted 
    $(0.17) 
    $(0.19) 
    $(0.20) 
    $(0.38)

    Weighted average common shares outstanding 
     24,021,546  
     11,389,308  
     20,148,211  
     10,655,483 

The
accompanying notes are an integral part of these unaudited consolidated financial statements

6

bioAffinity
Technologies, Inc.

Unaudited
Consolidated Statements of Changes in Stockholders’ Equity

    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Deficit  
    Equity 

    For the Six Months Ended June 30, 2025 

    Preferred Stock  
    Common Stock  
    Additional  Paid-in  
    Accumulated  
    Stockholders’
                                                                    Equity 

    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Deficit  
     (Deficit) 

    Balance at December 31, 2024 
     —  
    $—  
     15,227,619  
    $106,593  
    $56,139,753  
    $(53,644,310) 
    $2,602,036 

    Stock-based compensation expense 
     —  
     —  
     294,068  
     2,059  
     536,164  
     —  
     538,223 

    Sale of common stock, net 
     —  
     —  
     7,784,904  
     54,494  
     187,834  
     —  
     242,328 

    Exercise of stock warrants 
     —